retatrutide logo Retatrutide, Eli Lilly's next generation of weight loss injections, showed dramatic results in clinical trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli retatrutide logo Retatrutide Vial Label

Ayuda a las mitocondrias, las enzimas responsables de producir energa, a repararse hasta cierto punto y a generar energa

99.86% independently tested by Freedom Diagnostics via HPLC with UV Detection and Mass Spectrometry (LCMS/MS)

These are 1000 mcg, given once a month

How weight-loss drugs may be fueling eating disorders The rise of GLP-1 medications hailed as revolutionary tools for weight loss may be fueling a troubling trend: the onset or worsening of eating disorders

If future court rulings or FDA actions restrict compounded tirzepatide availability, patients may need to transition to brand-name products or alternative medications